Kurzfassung

A phase 3, randomized, double-blind, multicenter study to evaluate the efficacy and safety of intravenous iclaprim versus vancomycin in the treatment of acute bacterial skin and skin structure infections suspected or confirmed to be due to gram-positive pathogens